Operators are excited about a device that avoids transapical access, a limitation of other systems, says Gilbert Tang.

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below: Receive the the latest news, research, and presentations from major meetings ...

Edwards Lifesciences (NYSE: EW) today shared new data demonstrating successful outcomes with its mitral and tricuspid ...

For high-risk surgical patients with severe symptomatic mitral regurgitation (MR), insertion of the Tendyne transcatheter mitral valve replacement (TMVR; Abbott) using a cardiac transapical approach ...

Venus Medtech's Cardiovalve subsidiary announced today that it completed enrollment in a study of its tricuspid valve ...

Vibhu Parcha, M.D., a clinical research fellow in the UAB Division of Cardiovascular Disease, says this study was an extensive surveillance exercise at a national level to look into the implications ...

Cardiac Dimensions, a Kirkland, Wash., company with a technology to treat heart valve malfunction, has raised $53 million from investors. Its total funding is more than $200 million. Cardiac ...